Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA gives go-ahead for 5-FP clinical trials

May 24, 1996

Gemzar approved in U.S.

May 24, 1996

Glaxo Wellcome's new dihydrofolate reductase inhibitor 195U89

May 24, 1996

MGI-114 receives patent protection in U.S.

May 24, 1996

Ribonucleotide reductase inhibitor 3-AP in development at Vion

May 17, 1996

BioChem Therapeutic will codevelop VX-710 in Canada

May 17, 1996

SmithKline Beecham claims hemoregulatory agents

May 17, 1996

Mitsui Toatsu claims antitumor trifluorothymidine derivatives

May 17, 1996

Patent coverage obtained for Immune Response's cell therapy for B cell lymphoma

May 17, 1996

Supplemental NDA filed for Novantrone in U.S.

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...